The utility of immunotherapy plus chemotherapy in gastric cancer has been justified; however, the target population and the role of PD-L1 expression in patient selection and management still need further investigation, which may differ from single-agent immunotherapy. This evidence concerns the gene CD274 and gastric cancer.